Document Detail

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.
MedLine Citation:
PMID:  22644089     Owner:  NLM     Status:  MEDLINE    
Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.
Mohammed A Omair; Khalid A Alnaqbi; Peter Lee
Related Documents :
22454809 - Methamphetamine-induced paralytic ileus.
536159 - Intralesional steroids in conservative management of subglottic stenosis of the larynx.
22843749 - A rare but severe pulmonary side effect of cetuximab in two patients.
20454809 - Post-intubation long-segment tracheal stenosis of the posterior wall: a case report and...
20229469 - A report of csf leak as a complication of nasal packing for epistaxis.
22556329 - Bordetella holmesii meningitis in an asplenic patient with systemic lupus erythematosus.
1248349 - Anal fistula: a review of 82 cases.
3599149 - Retrieval of intravascular foreign bodies.
18331639 - Migration of superior vena cava stent.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-05-27
Journal Detail:
Title:  Clinical rheumatology     Volume:  31     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-31     Completed Date:  2012-12-11     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1259-61     Citation Subset:  IM    
Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage,  adverse effects*
Antibodies, Monoclonal / administration & dosage,  adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects*
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Antirheumatic Agents / administration & dosage*
Demyelinating Diseases / chemically induced*,  drug therapy
Immunoglobulin G / administration & dosage
Magnetic Resonance Imaging
Receptors, Tumor Necrosis Factor / administration & dosage
Severity of Illness Index
Spondylitis, Ankylosing / drug therapy*,  physiopathology
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 0/rituximab; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beware of the biologicals-hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1...
Next Document:  Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis.